GD
NKTR icon

Grandfield & Dodd’s Nektar Therapeutics NKTR Stock Holding History

Grandfield & Dodd’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,671
Closed -$80K – 194
2022
Q3 		$80K Sell
1,671
-583
-26% -$34.7K 0.01% 185
2022
Q2 		$130K Sell
2,254
-676
-23% -$42.7K 0.01% 191
2022
Q1 		$240K Buy
2,930
+224
+8% +$33.2K 0.02% 186
2021
Q4 		$550K Buy
2,706
+711
+36% +$154K 0.04% 132
2021
Q3 		$540K Buy
1,995
+124
+7% +$29.8K 0.04% 130
2021
Q2 		$480K Buy
1,871
+57
+3% +$15.8K 0.03% 134
2021
Q1 		$540K Buy
1,814
+147
+9% +$45.8K 0.04% 129
2020
Q4 		$430K Buy
1,667
+138
+9% +$35.7K 0.03% 132
2020
Q3 		$380K Buy
1,529
+33
+2% +$10.4K 0.03% 138
2020
Q2 		$520K Buy
1,496
+244
+19% +$76.1K 0.05% 121
2020
Q1 		$335K Buy
1,252
+204
+19% +$63.1K 0.04% 135
2019
Q4 		$339K Buy
+1,048
New +$304K 0.03% 145

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Grandfield & Dodd's NKTR Position: Q4 2022 in Review

Grandfield & Dodd sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 1,671 shares — an estimated $80K sold.

Grandfield & Dodd first reported a position in NKTR in Q4 2019 and held it in 12 quarters. The position peaked at $550K in Q4 2021. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

  • Grandfield & Dodd reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Grandfield & Dodd sold 1,671 Nektar Therapeutics shares in Q4 2022, an estimated $80K.
  • Grandfield & Dodd first reported a position in Nektar Therapeutics in Q4 2019 and held it in 12 quarters.
  • Grandfield & Dodd's Nektar Therapeutics position peaked at $550K in Q4 2021.
  • 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Grandfield & Dodd's 13F filing for Q4 2022, filed 20 Jan 2023.